Table 1.
Baseline Characteristics of Study Population
| Characteristic | Overall Study Population (N=121) | Placebo (n=60) | Febuxostat (n=61) |
|---|---|---|---|
| Male sex, n (%) | 98 (81.0) | 48 (80.0) | 50 (82.0) |
| Age, y | |||
| Mean (SD) | 53.6 (10.6) | 55.1 (10.6) | 52.2 (10.5) |
| Range | 26 to 77 | 26 to 77 | 27 to 76 |
| Race, n (%) | |||
| American Indian or Alaska Native | 1 (0.8) | 0 | 1 (1.6)a |
| Asian | 15 (12.4) | 7 (11.7) | 8 (13.1) |
| Black | 21 (17.4) | 11 (18.3) | 10 (16.4) |
| White | 83 (68.6) | 42 (70.0) | 41 (67.2) |
| Other | 1 (0.8) | 0 | 1 (1.6) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 23 (19.0) | 9 (15.0) | 14 (23.0) |
| Not Hispanic or Latino | 98 (81.0) | 51 (85.0) | 47 (77.0) |
| Height (cm), mean (SD) | 172.72 (8.88) | 172.10 (8.56) | 173.33 (9.21) |
| Weight (kg), mean (SD) | 98.14 (20.46) | 95.35 (21.20) | 100.88 (19.49) |
| BMI (kg/m2), mean (SD) | 32.78 (5.57) | 31.99 (5.13) | 33.55 (5.91) |
| Smoking history, n (%) | |||
| Never smoked | 62 (51.2) | 32 (53.3) | 30 (49.2) |
| Ex‐smoker | 41 (33.9) | 20 (33.3) | 21 (34.4) |
| Current smoker | 18 (14.9) | 8 (13.3) | 10 (16.4) |
| Alcohol history, n (%) | |||
| Never drank | 46 (38.0) | 26 (43.3)a | 20 (32.8)a |
| Ex‐drinker | 6 (5.0) | 2 (3.3) | 4 (6.6) |
| Current drinker | 69 (57.0) | 32 (53.3) | 37 (60.7) |
| Renal function,b n (%) | |||
| Moderately impaired | 13 (10.7) | 8 (13.3) | 5 (8.2) |
| Mildly impaired | 63 (52.1) | 33 (55.0) | 30 (49.2) |
| Normal | 45 (37.2) | 19 (31.7) | 26 (42.6) |
| Baseline sUA, n (%) | |||
| <0.48 mmol/L | 87 (71.9) | 40 (66.7) | 47 (77.0) |
| ≥0.48 mmol/L | 34 (28.1) | 20 (33.3) | 14 (23.0) |
| BP medication, n (%) | |||
| None | 34 (28.1) | 16 (26.7)a | 18 (29.5) |
| 1 BP medication | 76 (62.8) | 37 (61.7) | 39 (63.9) |
| 2 BP medications | 11 (9.1) | 7 (11.7) | 4 (6.6) |
| BP medication type, n (%) | |||
| ACEi/ARB | 51 (42.1) | 25 (41.7) | 26 (42.6) |
| β‐blockers | 15 (12.4) | 8 (13.3) | 7 (11.5) |
| Ca++ channel blockers | 15 (12.4) | 7 (11.7) | 8 (13.1) |
| Diuretics | 16 (13.2) | 10 (16.7) | 6 (9.8) |
| Other | 1 (0.8) | 1 (1.7) | 0 |
ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; sUA, serum uric acid.
a
Total proportion does not add up to 100% because of rounding.
b
Renal function was defined as moderately impaired (eGFR 30 to <60 mL/min), mildly impaired (60 to <90 mL/min), or normal (≥90 mL/min); eGFR was calculated using the Modification of Diet in Renal Disease formula.